Victoza (liraglutide [rDNA origin] injection) is now available in the United States, according to the product’s maker, Novo Nordisk.
The medication is the first once-daily human glucagon-like peptide 1 analog for treating type 2 diabetes. It is indicated in the United States as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. It can be used as monotherapy or in combination with oral anti-diabetic medications.
“Victoza has been extensively studied as monotherapy, as well as in combination with current anti-diabetic medications, and has consistently demonstrated glucose control in both scenarios,” said Alan J. Garber, MD, PhD, Professor of Medicine, Biochemistry and Molecular Biology, and Molecular and Cellular Biology at Baylor College of Medicine in Houston, in a company press release.
“Victosa will provide patients with an effective therapy for type 2 diabetes that no only lowers blood sugar, but shows weight loss and low risk of hypoglycemia.”